Sugi Predict

Sugi Predict / Targets / NPY4R

NPY4R

Neuropeptide Y receptor type 4 · P50391 · NPY4R on Sugi Atlas →

38,501 patent compounds predicted against NPY4R, 19,560 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2632460 SCHEMBL2632460 0.71 19/20
SCHEMBL2182662 SCHEMBL2182662 0.70 19/20
SCHEMBL2632463 SCHEMBL2632463 0.64 19/20
SCHEMBL2194718 SCHEMBL2194718 0.62 19/20
SCHEMBL2194622 SCHEMBL2194622 0.62 19/20
SCHEMBL870206 SCHEMBL870206 0.61 18/20
SCHEMBL1162113 SCHEMBL1162113 0.61 18/20
SCHEMBL2632215 SCHEMBL2632215 0.59 18/20
SCHEMBL2632397 SCHEMBL2632397 0.59 18/20
SCHEMBL2185394 SCHEMBL2185394 0.58 18/20
SCHEMBL1818349 SCHEMBL1818349 0.52 18/20
Leupeptin Leupeptin (SCHEMBL25361) 0.51 18/20
SCHEMBL2189528 SCHEMBL2189528 0.50 18/20
SCHEMBL241711 SCHEMBL241711 0.64 17/20
SCHEMBL241712 SCHEMBL241712 0.64 17/20
SCHEMBL1660343 SCHEMBL1660343 0.63 17/20
SCHEMBL1661018 SCHEMBL1661018 0.63 17/20
SCHEMBL2192841 SCHEMBL2192841 0.60 17/20
SCHEMBL2632395 SCHEMBL2632395 0.59 17/20
SCHEMBL2193850 SCHEMBL2193850 0.58 17/20

Clinical trials — most relevant to NPY4R by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation PHASE4COMPLETED
Medication, Weight Gain and GI Hormones PHASE4COMPLETED
Saxenda: Underlying Mechanisms and Clinical Outcomes PHASE4ACTIVE_NOT_RECRUITING
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion PHASE4RECRUITING
Long Term Extension Trial of Setmelanotide PHASE2/PHASE3COMPLETED
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA) PHASE3COMPLETED
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep PHASE3COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment PHASE1/PHASE2RECRUITING
Effects of Exenatide on Hypothalamic Obesity PHASE1/PHASE2COMPLETED
Repurposing Semaglutide for the Treatment of Cocaine Use Disorder PHASE2RECRUITING
Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36 PHASE1/PHASE2COMPLETED
Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers PHASE2COMPLETED
Effects of RM-493 on Energy Expenditure in Obese Individuals PHASE1COMPLETED
Degradation of the Anorexic Hormone Peptide YY EARLY_PHASE1COMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma nanCOMPLETED
Functional MRI Evaluation of Brain Response to Visual Food Stimulation in Morbidly Obese Patients Before and After Bariatric Surgery nanCOMPLETED
Brain-Derived Neurotrophic Factor in Obesity and Brain Function nanCOMPLETED
Auricular Vagus Stimulation in Obesity nanACTIVE_NOT_RECRUITING
The Role of Peptide YY (PYY)in Inhibiting Food Intake. nanCOMPLETED
The Effect of Weekly Semaglutide Treatment on Energy Expenditure nanCOMPLETED
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors nanCOMPLETED
Macronutrient Regulation of Ghrelin and Peptide YY nanCOMPLETED
The Progress of Diabetes After Supaglutide Treatment in Type 2 Diabetes Patients nanRECRUITING
Acylated Ghrelin Response to Acute Exercise in Obesity nanCOMPLETED
Impact of Sleep and Meal Timing on Food Intake Regulation nanCOMPLETED
The Role of GLP-1 in Satiety Perception in Humans nanWITHDRAWN
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention nanNOT_YET_RECRUITING
Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome nanCOMPLETED
RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis nanCOMPLETED
Probiotic Supplementation in Severe Depression nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NPY4R binder may also engage these)

ProteinNameSimilarity
P0DQD5 — 1.000 P0DQD5 →
Q63447 — 1.000 Q63447 →
Q61041 — 0.998 Q61041 →
Q61212 — 0.975 Q61212 →
P79217 — 0.972 P79217 →
O02835 — 0.964 O02835 →
Q9GLX8 — 0.964 Q9GLX8 →
P79113 — 0.963 P79113 →
O70526 — 0.962 O70526 →
P25023 — 0.962 P25023 →
Q9WVD0 — 0.961 Q9WVD0 →
Q1RMU8 — 0.960 Q1RMU8 →
Q28642 — 0.960 Q28642 →
O02813 — 0.959 O02813 →
P21555 — 0.959 P21555 →
P34992 — 0.958 P34992 →
O02836 — 0.958 O02836 →
P32299 — 0.958 P32299 →
O97661 — 0.957 O97661 →
NPY2R Neuropeptide Y receptor type 2 0.957 landscape →
P97295 — 0.956 P97295 →
P30551 — 0.956 P30551 →
Q9GK74 — 0.956 Q9GK74 →
Q5IS62 — 0.955 Q5IS62 →
Q04573 — 0.955 Q04573 →
Q9H1Y3 — 0.955 Q9H1Y3 →
Q924H0 — 0.955 Q924H0 →
BDKRB2 B2 bradykinin receptor 0.954 landscape →
Q99463 — 0.954 Q99463 →
HCRTR1 Orexin/Hypocretin receptor type 1 0.954 landscape →